Jones Financial Companies Lllp Has $578,000 Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)
Jones Financial Companies Lllp increased its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) ...
pharmaphorum8d
Regeneron set for August FDA decision on BCMA bispecific
Another factor for clinicians to consider is that linvoseltamab and Tecvayli are given intravenously, while Elrexfio and ABBV-383 can be administered by subcutaneous injection. Regeneron’s ...
Nasdaq16d
Regeneron Pharmaceuticals Reports Positive Results for Investigational Gene Therapy DB-OTO in Children with Otoferlin-Related Hearing Loss
In the initial dose-escalation cohort (Part A), participants receive a single intracochlear injection ... applications of products marketed or otherwise commercialized by Regeneron and/or its ...
Morningstar4d
Dupixent® (dupilumab) Late-Breaking Positive Pivotal Data in Bullous Pemphigoid Presented at AAD
It’s an injection given under the skin (subcutaneous ... and/or its collaborators or licensees (collectively, “Regeneron’s Products”) and product candidates being developed by Regeneron ...
Regeneron Pharmaceuticals, Inc.: Linvoseltamab Recommended for EU Approval by the CHMP to Treat Relapsed/Refractory Multiple Myeloma
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human ...
Regeneron Pharmaceuticals, Inc. (REGN) Leerink Partners 2025 Global Healthcare Conference Call Transcript
Regeneron Pharmaceuticals, Inc. ( NASDAQ: REGN) Leerink Partners 2025 Global Healthcare Conference Call March 11, 2025 8:00 AM ET ...
Yahoo Finance3d
Regeneron Pharmaceuticals, Inc. (REGN)
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the resubmission of the Biologics License Application (BLA ...
Morningstar13d
Linvoseltamab Recommended for EU Approval by the CHMP to Treat Relapsed/Refractory Multiple Myeloma
TARRYTOWN, N.Y., Feb. 28, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for ...